List of Excipients in Branded Drug NITROFURANTOIN (MACROCRYSTALS)

Generic Drugs Containing NITROFURANTOIN (MACROCRYSTALS)

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	nitrofurantoin (macrocrystals)	50090-7308	FERRIC OXIDE YELLOW
A-S Medication Solutions	nitrofurantoin (macrocrystals)	50090-7308	FERROSOFERRIC OXIDE
A-S Medication Solutions	nitrofurantoin (macrocrystals)	50090-7308	GELATIN
A-S Medication Solutions	nitrofurantoin (macrocrystals)	50090-7308	LACTOSE MONOHYDRATE
A-S Medication Solutions	nitrofurantoin (macrocrystals)	50090-7308	POTASSIUM HYDROXIDE
A-S Medication Solutions	nitrofurantoin (macrocrystals)	50090-7308	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in NITROFURANTOIN (MACROCRYSTALS)?

# Of NDCs	Excipient
2	FERRIC OXIDE RED
4	FERRIC OXIDE YELLOW
4	FERROSOFERRIC OXIDE
4	GELATIN
4	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE

Nitrofurantoin Macrocrystals Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Nitrofurantoin macrocrystals is an established, genericized urinary anti-infective with limited composition-of-matter or formulation-patent protection. Commercial value is concentrated in manufacturing efficiency, reliable dissolution, capsule differentiation, supply continuity, and channel-specific products rather than exclusivity.

The core excipient strategy is conservative: preserve the macrocrystalline active pharmaceutical ingredient, maintain food-associated bioavailability, control capsule performance, and reduce excipient-related barriers such as lactose intolerance, animal-derived gelatin, colorants, and poor moisture stability.

What is nitrofurantoin macrocrystals and how does it differ from Macrobid?

Nitrofurantoin macrocrystals is a crystalline form of nitrofurantoin designed to dissolve more slowly than smaller-particle nitrofurantoin. The slower dissolution is associated with reduced gastrointestinal irritation compared with microcrystalline nitrofurantoin. Macrodantin is the historical macrocrystal capsule product. Macrobid contains nitrofurantoin monohydrate and macrocrystals in a modified-release capsule formulation.

Product	Active form	Typical strength	Dosage form	Commercial distinction
Macrodantin	Nitrofurantoin macrocrystals	25 mg, 50 mg, 100 mg	Immediate-release capsule	Macrocrystal formulation
Generic nitrofurantoin macrocrystals	Nitrofurantoin macrocrystals	25 mg, 50 mg, 100 mg	Capsule	Therapeutically equivalent generic products
Macrobid	Nitrofurantoin monohydrate/macrocrystals	100 mg	Modified-release capsule	Distinct formulation and dosing schedule
Furadantin	Nitrofurantoin	25 mg/5 mL	Oral suspension	Liquid dosage form, different excipient and administration profile

Macrodantin labeling directs administration with food or milk to improve absorption and tolerability. The food effect is therefore a central development and quality-control consideration for any reformulated macrocrystal capsule.[1]

What excipients are used in nitrofurantoin macrocrystal capsules?

Historical Macrodantin capsule formulations use conventional solid-dose excipients, including lactose, corn starch, magnesium stearate, and talc. Capsule shells may contain gelatin, titanium dioxide, and colorants depending on strength and manufacturer.[1]

The commercial baseline is uncomplicated:

Excipient function	Common material	Development purpose
Diluent	Lactose	Capsule fill-volume adjustment
Disintegrant or binder	Corn starch	Capsule plug breakup and powder processing
Lubricant	Magnesium stearate	Ejection and tooling performance
Glidant or anti-adherent	Talc	Flow and processing control
Capsule shell	Gelatin	Standard hard-shell capsule platform
Opacifier or colorant	Titanium dioxide and approved pigments	Product identification and light protection

The main formulation risk is not chemical instability alone. It is the interaction between particle-size distribution, powder flow, capsule fill uniformity, dissolution, and food-associated exposure.

What is the optimal excipient strategy for nitrofurantoin macrocrystals?

The preferred strategy is a platform formulation with limited excipient changes and a controlled macrocrystal specification.

Maintain the macrocrystal particle-size profile

The active ingredient is the primary performance variable. Reducing particle size can increase dissolution and alter gastrointestinal exposure, even if the nominal dose remains unchanged. A developer should control:

• D10, D50, and D90 particle-size distribution
• Crystal morphology
• Specific surface area
• Bulk and tapped density
• Polymorphic or hydrate state
• Residual solvent and water content
• Dissolution across physiologically relevant pH conditions

A formulation that uses the same excipients as a reference product but changes the macrocrystal particle-size profile may not be clinically equivalent in performance.

Use a low-risk capsule-fill system

A lactose, starch, and magnesium stearate system is commercially proven. It is likely to minimize development risk, although lactose-free and animal-free variants offer differentiation.

Potential alternatives include:

• Microcrystalline cellulose as a lactose replacement
• Pregelatinized starch for improved compactibility and flow
• Colloidal silicon dioxide for flow control
• Sodium starch glycolate or low-substituted hydroxypropyl cellulose for disintegration
• Calcium stearate or sodium stearyl fumarate as alternative lubricants
• Hypromellose capsules as a gelatin substitute

Each substitution requires comparative dissolution, content uniformity, stability, and bioequivalence assessment. Excipients that improve wetting or disintegration can unintentionally increase dissolution relative to the macrocrystal reference.

Avoid aggressive wetting systems

Surfactants and high levels of hydrophilic polymers may improve dissolution but can undermine the intended macrocrystal release behavior. They also may change food-effect performance. A surfactant-based formulation is therefore a higher-risk strategy unless it addresses a documented manufacturing or bioavailability problem.

Use moisture control selectively

Nitrofurantoin products should be evaluated for moisture sensitivity, capsule-shell interactions, and storage performance. A moisture-barrier bottle, desiccant, or high-barrier blister may provide more commercial value than adding complex excipients to the fill blend.

What formulations are protected by nitrofurantoin patents?

The historical nitrofurantoin macrocrystal product is an old small-molecule formulation. Its original composition and formulation protections are expired or commercially immaterial in the United States. The current opportunity is not based on broad patent exclusivity.

Potentially protectable areas include:

• A defined macrocrystal particle-size distribution
• A specific polymorphic or hydrate-controlled form
• A lactose-free or gelatin-free composition
• A moisture-stable capsule system
• A low-impurity manufacturing process
• A specific dissolution profile
• A pediatric or geriatric administration platform
• A combination of macrocrystals with a defined excipient ratio
• A packaging system that maintains stability under accelerated conditions

Patentability will depend on unexpected technical effects. Merely replacing lactose with microcrystalline cellulose or gelatin with hypromellose is unlikely to create a strong estate without comparative performance data.

What is the Orange Book status of nitrofurantoin macrocrystals?

Nitrofurantoin macrocrystal capsules are a mature generic product category. The commercial reference product is associated with Macrodantin and NDA 016620. The relevant FDA pathway for new entrants is generally an abbreviated new drug application under section 505(j), not a new chemical entity pathway.[2]

The commercial implications are:

Issue	Assessment
New chemical entity exclusivity	Expired
Orphan exclusivity	Not applicable
Biosimilar pathway	Not applicable
Reference-product patent barrier	Limited for the macrocrystal capsule category
ANDA pathway	Primary route for generic entry
Paragraph IV exposure	Generally low unless a newly listed formulation patent is identified
Formulation differentiation	Possible, but requires equivalence support
Regulatory complexity	Moderate because particle size and dissolution are performance-critical

Orange Book patent listings can change through new listing activity, delisting, or product-specific updates. A launch decision should be based on the current FDA Orange Book entry for the specific reference product and dosage form.[3]

When does nitrofurantoin macrocrystals lose exclusivity?

Nitrofurantoin macrocrystals lost meaningful exclusivity decades ago. No current commercial thesis should rely on an upcoming patent cliff. The relevant issue is generic competition and the ability to obtain or retain market share.

Macrodantin has no remaining new-product exclusivity that would normally prevent ANDA competition. Macrobid has a separate formulation history and should not be treated as identical to the macrocrystal capsule product for patent, regulatory, or clinical analysis.

Patent-expiration assessment

Protection category	Current commercial position
Nitrofurantoin composition of matter	Expired
Original macrocrystal formulation	Expired or no longer commercially blocking
Historical brand exclusivity	Expired
New excipient formulation	Potentially patentable if technically non-obvious
Manufacturing process	Potentially patentable, but trade-secret protection may be stronger
Packaging and stability system	Potentially protectable, usually narrow
Method of use	Limited value for an established antibacterial indication

Which companies are challenging nitrofurantoin macrocrystals?

The category has historically been served by multiple generic manufacturers rather than a single active patent challenger. Generic competition can include ANDA products from companies such as Actavis, Teva, Mylan, Sandoz, Amneal, Rising, and other suppliers, subject to current FDA approvals and commercial availability.

Because the product is mature, competitive activity is more likely to involve:

• ANDA approval and product launch
• Authorized-generic supply
• Contract manufacturing
• National wholesaler contracting
• Pharmacy substitution
• Temporary supply interruptions
• Re-entry after manufacturing remediation

Paragraph IV litigation is not the principal market driver for an old macrocrystal capsule. The absence of a major current patent dispute does not eliminate launch risk. It shifts the risk toward FDA approval timing, manufacturing readiness, pricing, and access to pharmacy channels.

What generic launch risks exist for nitrofurantoin macrocrystals?

The principal launch risks are technical and commercial.

Bioequivalence risk

Food can materially affect nitrofurantoin absorption. The product must be evaluated under the FDA’s applicable bioequivalence requirements, including the relevant fed and fasting conditions.[2] A reformulation that changes wetting, disintegration, or particle dispersion can produce exposure differences.

Dissolution risk

The generic should demonstrate comparable dissolution behavior across the required media and time points. A formulation that dissolves substantially faster may increase gastrointestinal exposure or fail to match the reference product’s in vitro profile.

Content-uniformity risk

Low-dose 25 mg capsules are more sensitive to segregation and fill-weight variation than 100 mg capsules. The active-to-excipient ratio, blending order, lubricant exposure, and powder-density differences need close control.

Manufacturing risk

Macrocrystalline nitrofurantoin may create flow and segregation challenges. Important controls include:

• Narrow active particle-size distribution
• Low-shear blending
• Validated lubrication time
• Capsule-fill weight control
• Environmental humidity control
• Container-closure integrity
• Supplier qualification for active and capsule-shell materials

Market-access risk

Nitrofurantoin macrocrystals is a low-cost generic category. A technically differentiated product can still fail commercially if it lacks wholesaler coverage, pharmacy stocking, or dependable supply.

How can excipient reformulation create commercial opportunities?

Lactose-free nitrofurantoin macrocrystals

A lactose-free product can target patients and institutions seeking simplified excipient profiles. The opportunity is commercially credible but limited by the low price of the underlying drug. The product needs a clear label-level distinction, reliable supply, and payer or institutional adoption.

Microcrystalline cellulose and pregelatinized starch are practical starting points. The formulation should preserve capsule fill density and dissolution without introducing a faster-release profile.

Gelatin-free capsules

Hypromellose capsules can address vegetarian, religious, and animal-origin restrictions. This is a useful institutional and international-market feature. The principal risks are capsule moisture permeability, brittleness, fill-machine compatibility, and cost.

Colorant-reduced products

A colorant-free or titanium-dioxide-free capsule can support clean-label positioning and simplify regional registration. The value is strongest where institutional formularies or local regulatory rules restrict colorants.

Pediatric and geriatric presentations

Nitrofurantoin macrocrystal capsules are not suitable for children under one month of age because of the risk of hemolytic anemia associated with immature erythrocyte enzyme systems.[1] A pediatric opportunity therefore requires careful age targeting and may favor a separate suspension or dispersible technology rather than simply opening capsules.

For older adults, a smaller capsule, improved swallowability, and clear administration instructions may be more commercially useful than a new excipient claim.

Hospital and long-term-care packaging

Unit-dose blister packs, calendar packaging, and moisture-protective formats may generate more defensible commercial differentiation than an excipient-only change. Long-term-care facilities may value barcode compatibility, tamper evidence, and reduced medication-administration errors.

How strong is the patent estate for nitrofurantoin macrocrystals?

The legacy patent estate is weak for blocking purposes. A new entrant would face a low composition-of-matter barrier but a moderate execution barrier.

Patent-estate component	Strength
Core active ingredient	Very weak
Macrocrystal concept	Weak
Conventional capsule excipients	Weak
Defined particle-size specification	Moderate if linked to unexpected results
Novel moisture-control system	Moderate
Manufacturing process	Moderate to strong if difficult to reproduce
New delivery system	Potentially strong, but regulatory burden increases
Method-of-use claims	Weak for standard uncomplicated urinary tract infection use

Trade secrets may be more valuable than patents for crystal growth, milling, particle classification, blending, and impurity control. A company with a low-cost, consistent supply process can defend margin without relying on broad patent exclusion.

What licensing deals and partnerships are commercially relevant?

Large royalty-bearing licenses are unlikely for the base macrocrystal capsule because the product is genericized. Partnership opportunities are more likely to involve:

• API supply agreements
• Contract development and manufacturing
• Authorized-generic arrangements
• Regional commercialization rights
• Institutional supply contracts
• Capsule-shell technology licensing
• Packaging and serialization services
• Reformulation rights for lactose-free or animal-free products

A partner with FDA-approved manufacturing capacity and established wholesaler access may be more valuable than a patent holder. The product’s low price makes fixed manufacturing cost, minimum order quantities, and supply reliability central deal terms.

How does nitrofurantoin macrocrystals compare with Macrobid?

Macrobid is commercially stronger as a differentiated product because its monohydrate/macrocrystal formulation supports twice-daily dosing. Nitrofurantoin macrocrystals generally requires more frequent administration under its labeling.[1,4]

Factor	Nitrofurantoin macrocrystals	Macrobid
Core formulation	Macrocrystals	Monohydrate plus macrocrystals
Usual adult dosing concept	More frequent dosing	Twice daily
Capsule platform	Conventional capsule	Modified-release capsule
Differentiation	Excipient, supply, packaging, patient segment	Dosing convenience and release design
Generic competition	Mature	Mature but formulation-specific
Patent opportunity	Narrow	More complex formulation and release claims
Reformulation risk	Particle size and dissolution	Release kinetics, component ratio, food effect

A macrocrystal developer should not assume that a successful Macrobid-style release profile can be created by changing excipients in a conventional macrocrystal capsule. The regulatory target, clinical use pattern, and bioequivalence requirements are different.

What is the FDA regulatory status of nitrofurantoin macrocrystals?

The product is an FDA-approved prescription antibacterial available through the ANDA system. Regulatory attention centers on equivalence, labeling, manufacturing quality, and antimicrobial-use restrictions rather than new clinical efficacy development.[1,2]

A reformulated product may require:

• An ANDA referencing the applicable listed drug
• Comparative dissolution testing
• Fed and fasting bioequivalence studies
• Stability data
• Capsule-shell and excipient qualification
• Updated labeling for inactive ingredients
• Demonstration that the reformulation does not alter safety or administration requirements

A 505(b)(2) strategy may become relevant for a materially new dosage form, delivery system, or clinical use. It is less attractive for a conventional excipient substitution that can be supported through an ANDA.

What commercial strategy offers the best return?

The strongest near-term strategy is a low-cost, reliable ANDA product with one credible differentiator:

1. Lactose-free macrocrystal capsules.
2. Gelatin-free hypromellose capsules.
3. High-barrier unit-dose packaging.
4. Dual-source or vertically integrated API supply.
5. A 25 mg product optimized for content uniformity and institutional use.

A premium price is difficult to sustain in retail generic channels. The better commercial model is margin protection through supply reliability, fewer batch failures, lower freight and packaging costs, and targeted institutional contracts.

Key Takeaways

• Nitrofurantoin macrocrystals is a mature generic product with no meaningful legacy exclusivity barrier.
• Macrocrystal particle size, dissolution, food effect, and capsule-fill uniformity are the principal technical controls.
• Conventional excipients such as lactose, starch, magnesium stearate, and talc are low-risk but weakly differentiating.
• Lactose-free, gelatin-free, colorant-reduced, and moisture-protective products offer the clearest commercial opportunities.
• A new excipient combination is unlikely to support strong patent protection without unexpected dissolution, tolerability, stability, or manufacturing results.
• Manufacturing know-how and supply reliability may provide more value than broad formulation patents.
• Macrobid should be analyzed separately because its monohydrate/macrocrystal modified-release formulation is not equivalent to conventional macrocrystal capsules.
• The likely market entry route is an ANDA, with bioequivalence and product-quality execution driving launch timing.
• Paragraph IV litigation and biosimilar competition are not major current risks for the macrocrystal capsule category.

FAQs

Can nitrofurantoin macrocrystals be formulated without lactose?

Yes. Lactose can be replaced with materials such as microcrystalline cellulose or pregelatinized starch, but the reformulation must preserve capsule fill performance, dissolution, stability, and bioequivalence.

Is a gelatin-free nitrofurantoin macrocrystal capsule commercially viable?

Yes, particularly for institutional, international, vegetarian, and religious-diet markets. Hypromellose capsules are the leading alternative, although moisture transmission and machine compatibility require validation.

Can a new particle-size range support a nitrofurantoin patent?

Potentially, but a particle-size claim needs a technical effect that is unexpected and reproducible. A narrower particle-size range alone is unlikely to create a durable patent position.

Is nitrofurantoin macrocrystals suitable for pediatric use?

The labeled capsule product is not suitable for infants younger than one month. Pediatric development may require a separate liquid or dispersible formulation with its own stability, dosing, palatability, and bioequivalence strategy.[1]

Does nitrofurantoin macrocrystals have biosimilar competition?

No. Nitrofurantoin is a chemically synthesized small molecule. Competition occurs through generic drug applications, not biosimilar applications.

References

1. U.S. Food and Drug Administration. (2023). Macrodantin (nitrofurantoin macrocrystals) capsule prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2024). Nitrofurantoin macrocrystals: Product-specific guidance for generic drug development. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. U.S. Food and Drug Administration. (2023). Macrobid (nitrofurantoin monohydrate/macrocrystals) capsule prescribing information. FDA/DailyMed.